research Utilização De Finasterida No Tratamento Da Hiperplasia Prostática Benigna – Relato De Caso
Finasteride effectively treats BPH but requires continuous use to maintain benefits.
Search
forProducts matching "benign prostate enlargement"
Tracking 6 products like 132 URODART 0.5MG 28 capsule, 157 Finast (Finasteride 5mg), 163 Prosteride, 163 Prosteride and 165 Urimax D (Tamsulosin HCl/Dutasteride 0.4mg/0.5mg) from by companies like Minoxidil Express, Inhouse Pharmacy and ZeeMoreUncle. View all 6 products »
Sort by
Research
870-900 / 1000+ results research Inhibitor of 5α-Reductase Dutasteride in the Treatment of Benign Prostatic Hyperplasia: Systematic Review and Meta-Analysis
Dutasteride is more effective than finasteride for treating BPH without extra safety risks.
research 5α-Reductase Inhibitor Therapy: Should Physicians Be Concerned With Persistent Diminished Libido, Erectile Dysfunction, and Depression in a Subset of Patients?
Some patients may experience lasting sexual dysfunction, depression, and other side effects from 5α-reductase inhibitor therapy.
research Associations Between Semen Quality and Lower Urinary Tract Symptoms in Aging Males
The conclusion is that doctors should be careful when prescribing 5α-reductase inhibitors due to possible serious side effects, and they should discuss these risks with patients.
research Methylation of CpG Islands in Promoter of Type 2 5-Alpha Reductase and Implications of Finasteride Resistance for BPH Therapy
Methylation in specific gene region causes finasteride resistance in some BPH patients.
research Finasteride Does Not Prevent Bladder Cancer: A Secondary Analysis of the Medical Therapy for Prostatic Symptoms Study
Finasteride does not prevent bladder cancer.
research Phosphodiesterase Inhibitors Could Reverse the Proliferation of BPH Epithelial Cells Induced by CD8+ T Cells in Low Androgen Condition
Phosphodiesterase inhibitors like tadalafil can reduce cell growth in BPH caused by CD8+ T cells in low androgen conditions.
research Most Recent Findings of Curative Drugs for Lower Urinary Tract Symptoms in Clinical Practice
Current treatments for lower urinary tract symptoms include α1-blockers, 5ARIs, PDE5 inhibitors, anticholinergic agents, and β3-adrenergic receptor agonists.
research Structure of Human Type II 5 Alpha-Reductase Gene
The human type II 5α-reductase gene has a specific structure important for understanding certain medical conditions.
research Discontinuation of Alpha-Blockade After Initial Treatment With Finasteride and Doxazosin for Bladder Outlet Obstruction
Stopping alpha-blocker medication after 6-9 months is safe and effective for most patients with bladder outlet obstruction.
research Evaluation of Polymorphism Influence in Finasteride
Different forms of finasteride dissolve and remain stable differently, affecting capsule quality.
research This Month in Clinical Urology
New treatments and diagnostic methods for urological conditions show promise, but some lack sufficient accuracy for clinical use.
research Crystal Structure of Steroid Reductase SRD5A Reveals Conserved Steroid Reduction Mechanism
The structure of SRD5A reveals how it reduces steroids, aiding drug design for related health conditions.
research Dutasteride, A Novel Dual 5-Alpha Reductase Inhibitor, Reduces Serum DHT to a Greater Extent Versus Finasteride and Achieves Maximal Reduction in a Larger Proportion of Patients
Dutasteride reduces DHT more effectively than finasteride.
research Effects of 5-Alpha-Reductase Inhibitor (Finasteride) on Perioperative Blood Loss in Patients with BPH Undergoing TURP
Finasteride reduces blood loss and the need for blood transfusions during and after TURP surgery.
research Effect of 1 mg/Day Finasteride on Concentrations of Serum Prostate-Specific Antigen in Men With Androgenic Alopecia: A Randomized Controlled Trial
Taking 1 mg/day finasteride for hair loss significantly lowers PSA levels in men, which may affect prostate cancer screening.
research The Corpus Cavernosum After Treatment With Dutasteride or Finasteride: A Histomorphometric Study in a Benign Prostatic Hyperplasia Rodent Model
Dutasteride caused more penile tissue changes than finasteride, possibly increasing erectile dysfunction risk.
research Three-Month Treatment With a Long-Acting Gonadotropin-Releasing Hormone Agonist of Patients With Benign Prostatic Hyperplasia: Effects on Tissue Androgen Concentration, 5α-Reductase Activity and Androgen Receptor Content
A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.
research Finasteride and Erectile Dysfunction in Patients with Benign Prostatic Hyperplasia or Male Androgenetic Alopecia
Finasteride may increase erectile dysfunction risk in patients with benign prostatic hyperplasia.
research Is Radical Prostatectomy the Best Choice for Patients with Locally Advanced Prostate Cancer?
The document does not confirm if radical prostatectomy is the best treatment for locally advanced prostate cancer.
research Induction of Secreted WNT Factor WISP1/CCN4 by Human Prostate Stromal Cells Under Microenvironmental Hypoxia
Human prostate cells produce more WISP1/CCN4 when there's not enough oxygen.
research The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia
Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.
research The Dihydrotestosterone Hypothesis of Prostate Cancer and Its Therapeutic Implications
The document suggests that targeting the hormone DHT could be a more effective treatment for prostate cancer than targeting testosterone.
research Antiandrogen Drugs Lower Serum Prostate-Specific Antigen Levels in Hirsute Subjects: Evidence That Serum PSA Is a Marker of Androgen Action in Women
Antiandrogen drugs can reduce PSA levels in women with excess hair, suggesting PSA is a sign of male hormone activity in women.
research Rat Steroid 5α-Reductase Kinetic Characteristics: Extreme pH-Dependency of the Type II Isozyme in Prostate and Epididymis Homogenates
The activity of a specific rat enzyme in the prostate and epididymis is highly dependent on the acidity level.
research Androgenic Alopecia May Have Evolved to Protect Men from Prostate Cancer by Increasing Skin Exposure to Ultraviolet Radiation
Male pattern baldness might have evolved to help protect against prostate cancer by increasing UV radiation on the scalp.
research Relative Binding Affinity of Novel Steroids to Androgen Receptors in Hamster Prostate
New steroids were effective in blocking male hormone receptors in hamster prostates.
research Imaging Prostate Cancer With Technetium-99m Tricarbonyl Finasteride Dithiocarbamate
A new compound was effective for imaging prostate cancer in rats.
research Serum Androgens and Prostate-Specific Antigen Levels in Androgenetic Alopecia: Is There a Difference Between Frontal and Vertex Baldness?
Vertex baldness has higher DHT levels than frontal baldness, but testosterone and PSA levels are similar.
research S1 Opioid Receptor Agonists and Serum Prostate-Specific Antigen Level: Is There a Role for Prostate Cancer Control and Chemoprevention?
Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.